^
Association details:
| Biomarker: | PDGFRA amplification + NTRK2 fusion |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Mosaicism for receptor tyrosine kinase activation in a glioblastoma involving both PDGFRA amplification and NTRK2 fusion
Published date:
05/26/2021
Excerpt:
Here we report a case of a 26-year-old man with an NTRK2-rearranged IDH-wildtype glioblastoma… temporary response to the NTRK inhibitor larotrectinib. Re-biopsy after disease progression showed elimination of the NTRK2-rearranged tumor cell clones, with secondary emergence of a PDGFRA-amplified subclone....Intratumoral heterogeneity in glioblastoma has significant implications for tumor resistance to targeted therapies.
DOI:
10.1002/onco.13835
